YU5296A - Anti-obesity proteins - Google Patents
Anti-obesity proteinsInfo
- Publication number
- YU5296A YU5296A YU5296A YU5296A YU5296A YU 5296 A YU5296 A YU 5296A YU 5296 A YU5296 A YU 5296A YU 5296 A YU5296 A YU 5296A YU 5296 A YU5296 A YU 5296A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- obesity
- patients
- agents
- obesity proteins
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Dati pronalazak definiše proteine koji se koriste kao agensi protiv gojaznosti, i koji kada se daju pacijentima reguliše njihovo masno tkivo. Saglasno gore navedenome ovakvi agensi omogućavaju pacijentima da prevazidju njihove hendikepe sa preteranom gojaznošću odnosno značajno im smanjuje rizik od dijabetisa tipa II kao i od kardiovaskularnih oboljenja i kancera.The present invention defines proteins that are used as anti-obesity agents, and which, when administered to patients, regulate their adipose tissue. In accordance with the above, such agents enable patients to overcome their handicaps with excessive obesity, ie significantly reduce their risk of type II diabetes as well as cardiovascular diseases and cancer.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38104895A | 1995-01-31 | 1995-01-31 | |
| US38363895A | 1995-02-06 | 1995-02-06 | |
| US45095P | 1995-06-22 | 1995-06-22 | |
| US216195P | 1995-08-11 | 1995-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU5296A true YU5296A (en) | 1998-08-14 |
Family
ID=27484996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU5296A YU5296A (en) | 1995-01-31 | 1996-01-29 | Anti-obesity proteins |
Country Status (15)
| Country | Link |
|---|---|
| JP (1) | JPH10513451A (en) |
| KR (1) | KR19980701798A (en) |
| AR (1) | AR002956A1 (en) |
| AU (1) | AU703316B2 (en) |
| BR (1) | BR9606999A (en) |
| CA (1) | CA2211784A1 (en) |
| CO (1) | CO4480035A1 (en) |
| CZ (1) | CZ240497A3 (en) |
| FI (1) | FI973162A (en) |
| NO (1) | NO973515L (en) |
| NZ (1) | NZ301589A (en) |
| PE (1) | PE15197A1 (en) |
| PL (1) | PL321702A1 (en) |
| TR (1) | TR199600085A2 (en) |
| YU (1) | YU5296A (en) |
-
1996
- 1996-01-29 KR KR1019970705195A patent/KR19980701798A/en not_active Application Discontinuation
- 1996-01-29 BR BR9606999A patent/BR9606999A/en not_active Application Discontinuation
- 1996-01-29 YU YU5296A patent/YU5296A/en unknown
- 1996-01-29 AU AU47052/96A patent/AU703316B2/en not_active Withdrawn - After Issue
- 1996-01-29 CZ CZ972404A patent/CZ240497A3/en unknown
- 1996-01-29 CA CA002211784A patent/CA2211784A1/en not_active Abandoned
- 1996-01-29 CO CO96003533A patent/CO4480035A1/en unknown
- 1996-01-29 JP JP8523612A patent/JPH10513451A/en active Pending
- 1996-01-29 NZ NZ301589A patent/NZ301589A/en unknown
- 1996-01-29 PL PL96321702A patent/PL321702A1/en unknown
- 1996-01-30 PE PE1996000072A patent/PE15197A1/en not_active Application Discontinuation
- 1996-01-30 AR ARP960101202A patent/AR002956A1/en unknown
- 1996-01-31 TR TR96/00085A patent/TR199600085A2/en unknown
-
1997
- 1997-07-30 FI FI973162A patent/FI973162A/en unknown
- 1997-07-30 NO NO973515A patent/NO973515L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9606999A (en) | 1997-10-28 |
| TR199600085A2 (en) | 1996-08-21 |
| FI973162A0 (en) | 1997-07-30 |
| CA2211784A1 (en) | 1996-08-08 |
| AU703316B2 (en) | 1999-03-25 |
| PE15197A1 (en) | 1997-05-22 |
| NO973515L (en) | 1997-09-29 |
| NO973515D0 (en) | 1997-07-30 |
| PL321702A1 (en) | 1997-12-22 |
| AR002956A1 (en) | 1998-05-27 |
| CZ240497A3 (en) | 1998-01-14 |
| AU4705296A (en) | 1996-08-21 |
| JPH10513451A (en) | 1998-12-22 |
| FI973162A (en) | 1997-09-30 |
| NZ301589A (en) | 1999-02-25 |
| KR19980701798A (en) | 1998-06-25 |
| CO4480035A1 (en) | 1997-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001096587A3 (en) | Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus | |
| TR199901172T2 (en) | Newly substituted pyrazole derivatives. | |
| DE69526120D1 (en) | USE OF NEBIVOLOL AS AN ANTI-ATHEROGENIC AGENT | |
| MXPA03006771A (en) | Modified antibodies and methods of use. | |
| DE60001271D1 (en) | HYDROXYMATAIRESINOL IN CANCER PREVENTION | |
| ATE185149T1 (en) | IMMUNOGENIC COMPOUNDS WITH SPECIFIC ANTICYTOKINE EFFECT, METHOD OF PRODUCTION, PHARMACEUTICAL COMPOSITION AND REACTION KIT CONTAINING THE SAME | |
| ATE263571T1 (en) | USE OF ERYTHROPOIETIN AND IRON PREPARATIONS FOR THE PRODUCTION OF PHARMACEUTICAL COMBINATION PREPARATIONS FOR THE TREATMENT OF RHEUMATIC DISEASES | |
| MX9602689A (en) | Human therapeutic uses of bpi protein products. | |
| ATE450622T1 (en) | GENES AND PROTEINS FOR PREVENTION, PREDICTION, PROGNOSIS AND THERAPY OF CARDIOVASCULAR DISEASE | |
| ATE307886T1 (en) | NUCLEOTIDE SEQUENCES, PROTEINS, MEDICATIONS AND DIAGNOSTIC AGENTS FOR USE IN CANCER TREATMENT | |
| ATE368455T1 (en) | USE OF (+)-TRAMADOL, O-DEMETHYLTRAMADOL, O-DESMETHYL-N-MONO-DESMETHYL-TRAMADOL FOR THE THERAPY OF URINARY INCONTINENCE | |
| AU688101B2 (en) | Live vaccine for the treatment of tumour diseases | |
| ATE77751T1 (en) | MEANS FOR TREATMENT OF BONE DISEASES. | |
| FR2746110B1 (en) | METHOD OF TREATING GENE THERAPY OF HUMAN TUMORS AND CORRESPONDING RECOMBINANT VIRUSES | |
| YU5296A (en) | Anti-obesity proteins | |
| AU2002251754A1 (en) | Therapeutic modulation of the tumor inflammatory response | |
| AU6987696A (en) | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells | |
| BR9708005A (en) | Down regulation resistant convertase C3 | |
| ATE428438T1 (en) | MEDICAL COMPOSITION CONTAINING TCF-II | |
| DE69804466D1 (en) | ROBINIA PSEUDOACACIA LECTIN AND ITS USE | |
| ATE218064T1 (en) | IMMUNOGENIC TLP COMPOSITION | |
| PT883406E (en) | USE OF IL-7 IN THE TREATMENT OF AUTO-IMMUNE DISEASES IN PARTICULAR TO DIABETES MELLITUS INSULINODEPENDENTE | |
| ATE363072T1 (en) | MONOCLONAL ANTIBODIES AGAINST MXA AND MXB | |
| KR927003083A (en) | Antitumor Compositions Based on Polypeptides Having Human Interleukin 2 Activity | |
| ES2160927T3 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INTERFERED NATURAL HUMAN ALPHA. |